SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-281981
Filing Date
2022-11-10
Accepted
2022-11-10 08:02:56
Documents
15
Period of Report
2022-11-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d360420d8k.htm   iXBRL 8-K 29773
2 EX-1.1 d360420dex11.htm EX-1.1 200146
3 EX-5.1 d360420dex51.htm EX-5.1 39663
7 GRAPHIC g360420g1110023617811.jpg GRAPHIC 1990
  Complete submission text file 0001193125-22-281981.txt   462851

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA atai-20221110.xsd EX-101.SCH 2837
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE atai-20221110_lab.xml EX-101.LAB 17912
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atai-20221110_pre.xml EX-101.PRE 11222
9 EXTRACTED XBRL INSTANCE DOCUMENT d360420d8k_htm.xml XML 3393
Mailing Address 524 BROADWAY NEW YORK NY 10013
Business Address WALLSTRASSE 16 BERLIN 2M 10179 (617)-699-5876
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

IRS No.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40493 | Film No.: 221375039
SIC: 2834 Pharmaceutical Preparations